Clinical Trial

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infection in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment with B-cell Depletion Therapy
Protocol Amendment History 2 changes
notable Trial sites expanded: 1 -> 6 locations 2026-08-13
critical Recruitment opened 2026-07-23
Trial Details
NCT Number NCT07220915
Lead Sponsor Octapharma
Conditions Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
Enrollment 360 participants
Start Date 2026-06-10
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-12